More about

Methotrexate

News
January 02, 2024
2 min read
Save

Two-week methotrexate pause helps COVID booster response without significant flares

Two-week methotrexate pause helps COVID booster response without significant flares

In patients with immune-mediated inflammatory diseases, a 2-week pause of methotrexate after receiving a COVID-19 vaccine booster yielded a sustained, significantly increased antibody response, without serious flares, according to a study.

News
December 29, 2023
2 min read
Save

Autoimmune thyroid disease risk decreases after rheumatoid arthritis diagnosis

Autoimmune thyroid disease risk decreases after rheumatoid arthritis diagnosis

Adults have a decreased risk for developing autoimmune thyroid disease after being diagnosed with rheumatoid arthritis, with the risk even lower for those receiving disease-modifying antirheumatic drugs, according to study data.

News
December 06, 2023
2 min watch
Save

VIDEO: ‘Practice affirming’ findings from split-dosing methotrexate study at ACR

VIDEO: ‘Practice affirming’ findings from split-dosing methotrexate study at ACR

SAN DIEGO — In this video, Healio spoke with Jeffrey A. Sparks, MD, MMSc, results from a study conducted in India assessing the efficacy of treating rheumatoid arthritis with split-doses of methotrexate.

News
November 29, 2023
1 min read
Save

Triple combination therapy ‘superior to monotherapy,’ improves remission in Crohn’s

Triple combination therapy ‘superior to monotherapy,’ improves remission in Crohn’s

A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.

News
November 22, 2023
2 min watch
Save

VIDEO: Efficacious split-dosing of high-dose methotrexate in patients with RA

VIDEO: Efficacious split-dosing of high-dose methotrexate in patients with RA

SAN DIEGO — In this video, Healio spoke with Kathryn Dao, MD, about the SMART study presented at ACR Convergence 2023.

News
November 22, 2023
2 min read
Save

Split-dose methotrexate lowers need for more DMARDs vs single dose in rheumatoid arthritis

Split-dose methotrexate lowers need for more DMARDs vs single dose in rheumatoid arthritis

SAN DIEGO — Split-dose methotrexate had greater efficacy and reduced the need for additional disease-modifying antirheumatic drugs at 16 weeks vs. a single dose for rheumatoid arthritis, according to data presented at ACR Convergence 2023.

News
November 15, 2023
2 min read
Save

Patients with gout treated with pegloticase, methotrexate have lower blood pressure

Patients with gout treated with pegloticase, methotrexate have lower blood pressure

PHILADELPHIA — Pegloticase and methotrexate can be used to reduce blood pressure in patients with gout, hinting at a link between serum uric acid level and hypertension, according to data presented at the ASN Kidney Week conference.

News
September 30, 2023
2 min read
Save

Methotrexate shows longer efficacy in pediatric atopic dermatitis than cyclosporine

Methotrexate shows longer efficacy in pediatric atopic dermatitis than cyclosporine

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.

News
September 21, 2023
2 min read
Save

Adding methotrexate to pegloticase for gout increases response rate through 52 weeks

Adding methotrexate to pegloticase for gout increases response rate through 52 weeks

Patients who receive pegloticase alongside methotrexate for gout demonstrate higher response rates and fewer discontinuations, and were more likely to achieve tophi resolution, vs. those treated with pegloticase alone, according to data.

News
August 15, 2023
1 min read
Save

Dose-dense chemotherapy improves overall survival for bladder cancer at 5 years

Patients with muscle-invasive bladder cancer receiving dose-dense methotrexate, vinblastine, doxorubicin and cisplatinhad improved OS at 5 years compared with gemcitabine and cisplatin, according to a presentation at ASCO Annual Meeting.

View more